LAVAL, QC, Nov. 30 /PRNewswire-FirstCall/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) today announces the departure of Philippe Calais, PhD. Pharm., Neurochem's President, Global Business. Dr. Calais joined Neurochem in 2003, and is leaving effective December 31, 2007, to pursue other interests.
"Dr. Calais has made a significant contribution to creating constructive relationships for Neurochem in international markets and we are grateful for having had the benefit of his expertise during the five years he has been with us," said Dr. Francesco Bellini, Neurochem's Chairman, President and CEO. "We wish him every success in his new pursuits."
Neurochem Inc. is a global health company focused on the research, development and commercialization of products to provide innovative health solutions to patients suffering from serious diseases.
To Contact Neurochem
For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1 877 680-4500 or visit the Web Site at: http://www.neurochem.com.
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem's control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which Neurochem does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of Neurochem. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on the forward-looking statements included in this news release. These statements speak only as of the date made and Neurochem is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise. Please see the Annual Information Form for further risk factors that might affect the Company and its business.
For further information, please contact:
Lise Hebert, Ph.D. Tel: 1-450-680-4572
Vice President, Corporate Communications firstname.lastname@example.org
|SOURCE NEUROCHEM INC.|
Copyright©2007 PR Newswire.
All rights reserved